Redeye provides a brief comment on WntResearch’s initial phase 2 data. The results indicate that Foxy-5 has a good safety profile; however, it has limited clinical effects. Consequently, the company has decided to halt further recruitment and intends to terminate the ongoing study. We expect the company’s share to take a significant hit today. Furthermore, we will return with a longer note after the company’s live interview at 11:15 CET.